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LIM domain kinase 1 (LIMK1) is a key regulator of actin dynamics. It is thereby a potential
therapeutic target for the prevention of fragile X syndrome and amyotrophic lateral scler-
osis. Herein, we use X-ray crystallography and activity assays to describe how LIMK1
accomplishes substrate speciﬁcity, to suggest a unique ‘rock-and-poke’ mechanism of
catalysis and to explore the regulation of the kinase by activation loop phosphorylation.
Based on these ﬁndings, a differential scanning ﬂuorimetry assay and a RapidFire mass
spectrometry activity assay were established, leading to the discovery and conﬁrmation
of a set of small-molecule LIMK1 inhibitors. Interestingly, several of the inhibitors were
inactive towards the closely related isoform LIMK2. Finally, crystal structures of the
LIMK1 kinase domain in complex with inhibitors (PF-477736 and staurosporine, respect-
ively) are presented, providing insights into LIMK1 plasticity upon inhibitor binding.
Introduction
Fragile X syndrome (FXS) is a genetic disorder caused by a mutation in the Fragile X mental retard-
ation 1 (FMR1) gene [1]. Affected individuals show developmental delay and reduced intellectual abil-
ities, often paired with autism, social anxiety and hyperactivity [1]. With a prevalence of 1 in 6000
newborns, FXS is the most common hereditary cause of intellectual disability [1]. Amyotrophic lateral
sclerosis (ALS) is characterised by the impaired formation of motor neurons [2]. In affected indivi-
duals, the gradual loss of muscle functionality leads to difﬁculties in speaking, movement and breath-
ing [2]. ALS etiology is complex being associated with both genetic and environmental factors.
However, the most prominent genetic risk factor is a mutation in the C9ORF72 gene, accounting for
∼5% of cases [3]. ALS is classiﬁed a rare disease, with 2.6 in 100 000 people per year being diagnosed
with ALS in Europe [4]. As for FXS, there is no known cure [2]. Effective treatments are urgently
sought for both diseases.
While FXS and ALS differ in trigger, affected cell type, age of onset and clinical appearance, both
disorders share a common cellular characteristic in the deregulation of actin cytoskeleton dynamics
[5,6]. A deregulated cytoskeleton impairs multiple cellular functions such as motility, neurite growth
and vesicle transport. Actin-depolymerising factors (ADFs), namely coﬁlin-1 (CFL1), coﬁlin-2 (CFL2)
and destrin, are key regulators of actin cytoskeleton dynamics [7]. These small proteins with high
sequence identity decorate ADP-rich segments of actin ﬁlaments (generally the older segments), thus
promoting ﬁlament severing and disassembly [7]. This provides the cell with fresh ATP-actin mono-
mers with which to build new actin ﬁlaments as they are required.
The ADF activity, in turn, is regulated by phosphorylation, with several kinases inactivating, and
the phosphatase Slingshot homologue 1 (SSH1) [8] activating ADFs. The kinases capable of phos-
phorylating ADFs belong to the tyrosine kinase-like family of protein kinases and include the LIM
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domain kinases 1 and 2 (LIMK1 and LIMK2) [9] and the testis-speciﬁc kinases 1 and 2 (TESK1 and TESK2)
[10]. The contribution of an individual kinase to ADF phosphorylation is cell type-speciﬁc, developmental
stage-speciﬁc and thus difﬁcult to establish. In adult neurons, however, LIMK1 is regarded as the dominant
factor for ADF phosphorylation. LIMK1 accounts for 70%, LIMK2 for 15% and TESK1/2 for the residual 15%
of Phospho-ADFs, as determined by analysing the hippocampi of knockout mice [11].
LIMK1/2 activity is switched on by upstream kinases such as p21-activated kinase 1 and 4 (PAK1 and
PAK4), Rho-associated protein kinase 1 (ROCK1) and bone morphogenetic protein (BMP) receptor type-2
(BMPR2) [12]. These kinases, in turn, are regulated by Rho-family GTPases or directly by growth factors such
as the BMPs [12]. Thus, multiple signals converge on LIMK1/2, are integrated and translated into the ADF
phosphorylation level. Important aspects of the complex, but well-established ADF cascade are depicted in
Figure 1A.
Due to its crucial role in the phosphorylation of neuronal ADFs, LIMK1, in particular, has been identiﬁed as
a promising therapeutic target for the prevention of both FXS [13,14] and ALS [15]. Small-molecule inhibition
of LIMK1 kinase activity is expected to compensate for the effects of mutated FMR1 [13] and C9ORF72 [15],
respectively. Several LIMK1 inhibitors have been developed [16], most notably the now widely used LIMKi3
[17] (Figure 1B). The thiazole derivative shows high potency for LIMK1 (in vitro IC50 = 7 nM) and reasonable
selectivity against the kinome with 50-AMP-activated protein kinase (AMPK) being the most prominent kinase
off-target [17]. The inhibitory activity of LIMKi3 towards LIMK1 was also demonstrated in several cancer cell
lines [18] and in authentic prostate tissue [19], where a reduction in CFL1 phosphorylation was observed.
However, LIMKi3 is of limited use in biological settings, since it strongly interacts with tubulin [17]. The pyrro-
lopyrimidine LX-7101 [20] (Figure 1C) is another potent LIMK1 inhibitor (IC50 = 32 nM) with more moderate
kinome-wide selectivity. Notably, the favourable pharmacological properties of LX-7101 led to its investigative
use in phase I clinical trials for glaucoma [20]. Other LIMK1 inhibitors are less well characterized [21].
However, we are not aware of any LIMK1 inhibitor that does not inhibit LIMK2 with similar afﬁnity. This is
not surprising, since LIMK1 and LIMK2 share high sequence identity within their kinase domains (71%), with
the ATP-binding pocket residues being close to identical.
Both LIMK proteins exhibit the same domain architecture and have overlapping substrate speciﬁcities.
Although LIMK1 is more highly expressed in the brain and LIMK2 is more abundant in muscle tissue, most
tissues express both proteins (data from The Human Gene Atlas). Nonetheless, different regulatory mechanisms
and physiological roles are apparent as reﬂected in their knockout phenotypes in mice. In contrast with
LIMK1, LIMK2 is indispensable for the proper functionality of the eye [22] and in spermatogenesis [23].
Therefore, isoform-speciﬁc LIMK inhibitors would be valuable tools, both for deciphering the physiological
roles of the individual LIMK isoforms and for the validation of LIMK1 as a target for the treatment of FXS
and ALS. Ideally, these inhibitors will also serve as starting points for the development of therapeutics.
Figure 1. The ADF cascade regulates actin cytoskeleton dynamics.
(A) The ADF cascade regulates actin cytoskeleton dynamics. Several pathways converge in LIMK1/2. In both ALS and FXS, the
cascade is deregulated. (B) Chemical structure of LIMKi3, a widely used LIMK1 inhibitor characterized by high LIMK1 afﬁnity,
but unfavourable off-target activity [17]. (C) Chemical structure of LX-7101, a dual inhibitor targeting LIMK1 and ROCK1 [20].
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).3198
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Many aspects of LIMK1 structure and function are still to be completely characterised. A signiﬁcant develop-
ment was the recent publication of a 3.5 Å model of the LIMK1–CFL1 complex [24]. However, there remain
open questions regarding LIMK1’s substrate speciﬁcity and as yet there have been no published structural
models of LIMK1-inhibitor complexes. Here we show that LIMK1 robustly phosphorylates both serine and
tyrosine residues, establishing LIMK1 as a dual-speciﬁcity kinase. We also present a higher resolution structure
of the LIMK1–CFL1 complex as well as the ﬁrst structures of two LIMK1-inhibitor complexes. Finally, we
propose a new rock-and-poke mechanism for substrate phosphorylation by the LIM kinases.
Experimental
Compound libraries and peptides
The kinase inhibitor library L1200 and the inhibitors for activity assays and co-crystallisation were purchased
from Selleckchem. The peptides tested as LIMK1 substrates were purchased from Genscript (description in
Supplementary Table S2).
LIMK1KD and LIMK2KD cloning, expression and puriﬁcation
The cDNA coding for LIMK1 residues 330 to 637 was PCR ampliﬁed using the forward primer TACTTCCAA
TCCATGCCACACCGCATCTTCCG and the reverse primer TATCCACCTTTACTGTCAGCTCTCGCCGCGC
CGG. The cDNA coding for LIMK2 residues 330 to 632 was PCR ampliﬁed using the forward primer TACTT
CCAATCCATGGACCTAATCCATGGGGAGGTCCTGG and the reverse primer TATCCACCTTTACTGTCAC
AGGCCGTACTGCATGCTCACAG. Both PCR templates were taken from the Mammalian Gene Collection
(MGC). The PCR products were then inserted into the vector pFB-LIC-Bse via ligation independent cloning
(LIC) [25]. After the transposition of the coding sequence into an engineered Baculovirus genome (Bac-to-Bac,
Invitrogen), the viral DNA was transfected into Sf9 insect cells cultivated in InsectXpress medium (Lonza).
Protein expression was performed as previously described [26]. In brief, exponentially growing TriEx cells
(Novagen) at 2 × 106 cells/ml were infected 1 : 64 with virus stock, incubated for 66 h at 27°C under constant
shaking and harvested by centrifugation.
Cells were resuspended in lysis buffer (50 mM HEPES pH 7.4, 500 mM NaCl, 20 mM imidazole, 0.5 mM
TCEP, 5% glycerol) and lysed by sonication. The lysate was cleared by centrifugation and loaded onto a Ni NTA
column. After vigorous rinsing with lysis buffer, the His6-tagged proteins were eluted in lysis buffer containing
300 mM imidazole. While the proteins were subjected to dialysis to get rid of the imidazole, the N-terminal tags
were cleaved by TEV protease. Contaminating proteins, the cleaved tags and TEV protease were removed with
another Ni NTA step. Finally, the LIMK kinase domains were concentrated and subjected to gel ﬁltration using
an AKTA Xpress system combined with an S200 16/600 gel ﬁltration column (GE Healthcare). The elution
volumes of 91.8 ml (LIMK1KD) and 91.6 ml (LIMK2KD) indicated the proteins to be monomeric in solution. The
ﬁnal yields were 2.0 mg/L insect cell medium (LIMK1KD) and 0.2 mg/L insect cell medium (LIMK2KD).
CFL1 cloning, expression and puriﬁcation
cDNA coding for CFL1 (again taken from MGC) was PCR ampliﬁed using the forward primer TTAAGAAGG
AGATATACTATGGCCTCCGGTGTGGCTGTC and the reverse primer GATTGGAAGTAGAGGTTCTCTG
CCAAAGGCTTGCCCTCCAGGG. The PCR product was then inserted into the vector pNIC-CTHF via liga-
tion independent cloning [25]. The mutants S3C, S3T, S3Y, K112A, K112E, A118P and A118W were generated
by site-directed mutagenesis using the QuikChange kit (Agilent). The resulting plasmids were transformed into
E. coli DH10B, protein expression was performed as previously described [27]. In brief, bacteria were propa-
gated in TB medium at 37°C until the OD reached 1. Under constant shaking, the temperature was then
reduced to 18°C. After 30 min, IPTG was added to a ﬁnal concentration of 0.5 mM. The bacteria were incu-
bated for another 16 h at 18°C and harvested by centrifugation.
Cells were resuspended in lysis buffer (50 mM HEPES pH 7.4, 500 mM NaCl, 20 mM imidazole, 0.5 mM
TCEP, 5% glycerol) and lysed by three passages through the high-pressure cell breaker. The puriﬁcation was
carried out as described above for LIMK1KD. In the ﬁnal gel ﬁltration with the S75 16/600 column (GE
Healthcare), CFL1 eluted at 78.7 ml, indicating the protein to be monomeric in solution. The ﬁnal yield was
70 mg CFL1/L TB medium.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 3199
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Dynamic scanning ﬂuorimetry (DSF) assay
The assay was performed according to a previously established protocol [28]. A solution of 2 mM LIMK1KD in
assay buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 0.5 mM TCEP, 5% glycerol) was mixed 1 : 1000 with the
SYPRO Orange dye (Sigma). The compounds to be tested were added to a ﬁnal concentration of 10 mM. An
amount of 20 ml of each sample were placed in a 96-well plate and the temperature increased from 25 to 95°C.
Fluorescence was monitored using a Mx3005P real-time PCR instrument (Stratagene) with excitation and emis-
sion ﬁlters set to 465 and 590 nm, respectively. Data were analysed with the MxPro software. The screening
was performed as a single shot experiment. Potential LIMK1KD binders were further analysed in an activity
assay for conﬁrmation.
Rapidﬁre mass spec kinase activity assay
RapidFire mass spectrometry offers a high-throughput, label-free and direct measurement of substrate modiﬁ-
cations, including protein phosphorylation. This technology couples desalting by solid-phase extraction (SPE)
to rapid automated sample injection and processing to achieve high sampling rates. For inhibitor IC50 deter-
mination, the respective inhibitors in DMSO (11-point concentration series, all points in technical duplicates)
were dispensed to a 384-well polypropylene plate using an ECHO 550 acoustic dispenser (Labcyte). Then,
LIMK1KD was added (ﬁnal concentration 40 nM) to allow for 10 min pre-incubation at room temperature. The
phosphorylation reaction was initiated by adding a mixture of CFL1 (ﬁnal concentration 2 mM) and ATP (ﬁnal
concentration 800 mM). After 60 min incubation at room temperature, the reaction was stopped by adding
formic acid to a ﬁnal concentration of 1%. The reaction volume was 50 ml, and the assay buffer composition
was 50 mM Tris pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM MgCl2.
The plate was transferred to a RapidFire RF360 high-throughput sampling robot (Agilent). Samples were
aspirated under vacuum and loaded onto a C4 SPE cartridge and washed for 5.5 s with 0.1% (v/v) formic acid
in LCMS grade water to remove non-volatile buffer components. After the aqueous wash, analytes of interest
were eluted from the C4 SPE onto a 6530 Q-TOF LC/MS (Agilent) in an organic elution step (85% acetonitrile
in LCMS grade water containing 0.1% formic acid). Ion data for the CFL1 substrate and the Phospho-CFL1
product was extracted and peak area data integrated using RapidFire integrator software (Agilent). Finally, IC50
curves were generated using GraphPad Prism 7.
Crystallisation
Initially, the crystallisation of each sample was explored with 384 diverse precipitant solutions (four coarse
screens, namely HCS3, HIN3, JCSG7 and LFS6 purchased from Molecular Dimensions). Promising conditions
were optimised by modulating the concentrations, the pH and the volume of the respective precipitant solution.
To obtain mountable crystals, 100 nL-drops of the protein solution with the respective ligand were transferred
to a 3-well crystallisation plate (Swissci), mixed with 50 nL precipitant solution and incubated at 4°C (see
Table 1 for full protein, ligand and precipitant details). Crystals appeared overnight and did not change appear-
ance after 7 days. They were mounted in precipitant solution cryoprotected with additional 25% ethylene
glycol. Data were collected at Diamond Light Source, and analysed, scaled and merged with Xia2 [29]. The
structures were solved by molecular replacement with Phaser [30] using a Src model (PDB ID 1YI6) as a tem-
plate for LIMK1 and a CFL1 model (PDB ID 4BEX) as a template for CFL1. The models were reﬁned with
Refmac5 [31] and validated using MolProbity [32]. A summary of data collection and reﬁnement statistics is
given in Table 1. The models and structure factors have been deposited with the PDB IDs 5NXC, 3S95 and
5L6W, respectively.
Results and discussion
Structure of the LIMK1 kinase domain in complex with ATPγS and CFL1
To better characterise substrate recognition by LIMK1, we expressed and puriﬁed the recombinant LIMK1
kinase domain (LIMK1KD, Figure 2A) from insect cells and full-length CFL1 protein from E. coli. Suitable crys-
tals of the LIMK1KD–CFL1 complex were obtained using a non-phosphorylatable S3C mutant of CFL1 and the
non-reactive ATP analogue ATPγS. The structure of this complex was subsequently solved and reﬁned at 2.5 Å
resolution (Figure 2B, PDB ID 5L6W). In the resulting model, LIMK1KD adopted an active kinase conform-
ation with the ATP analogue bound as expected to the kinase hinge region within the ATP-binding pocket.
CFL1 was bound as a globular protein made up of a central antiparallel β sheet surrounded by seven α helices.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).3200
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Its N- and C-termini were situated at opposite sides of the molecule. CFL1 interacted with LIMK1 solely via its
α5 helix (the anchor helix) which spanned the full width of the LIMK1 kinase domain. This interaction placed
the CFL1 N-terminus containing the phosphoacceptor residue in close proximity to the ATP γ phosphate pos-
ition. Thus, the complex featured the act of phosphoryl transfer and conﬁrmed the recent ﬁndings by Hamill
et al. [24], who obtained a different crystal form, but the similar model (PDB ID 5HVK) using a catalytic
‘dead’ mutant (D460N) of LIMK1. The most striking difference to the previously published model was the
orientation of the substrate CFL1 towards LIMK1, which differed by an angle of 12° (Figure 2B). From the ana-
lysis of both structure models we deduced a so far undescribed catalytic mechanism that we refer to as the
rock-and-poke mechanism.
A rock-and-poke mechanism for LIMK1 catalytic activity
The structural models rationalised the high speciﬁcity of the LIMK1–CFL1 interaction. The LIMK1 interface
included parts of the activation loop as well as a large αF–αG loop insertion that displaced the usual αG helix
position to speciﬁcally accommodate the CFL1 anchor helix (Leu111 to Leu128, Figure 2C). Notably, CFL1
Lys112 was co-ordinated by three LIMK1 residues (Tyr514, Asp549 and Asp551) and was indispensable for
substrate recognition, as discussed below (Figure 2C). These interactions were supported by additional hydro-
phobic contacts including CFL1 Met115. While CFL1 was ﬁrmly attached to LIMK1, the 12° rotation between
the new structure and that of Hamill et al. suggested that the CFL1 molecule could rock back and forth around
Table 1 Crystallisation conditions, diffraction data collection and refinement statistics
PDB ID 5NXC 3S95 5L6W
Protein solution 10 mg/ml LIMK1KD 8.0 mg/ml LIMK1KD 6.5 mg/ml LIMK1KD, 3.5 mg/ml CFL1
With ligand 500 mM PF-477736 500 mM staurosporine 1.2 mM ATP-γ-S, 2.5 mM MgCl2
Precipitant solution 0.1 M HEPES pH 7.0,
0.2 M MgCl2, 10% PEG8K
0.1 M Tris pH 7.2, 10 mM
phenol, 24% MPD
0.1 M HEPES pH 7.5, 0.2 M KCl,
35% pentaerythritol propoxylate 5/4
Space group C 2 2 21 C 2 2 21 P 32 2 1
Cell parameters
a, b, c (Å) 88.39, 95.84, 84.39 106.16, 128.00, 131.35 80.68, 80.68, 237.59
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 120
Resolution (Å) 64.97–2.25 (2.30–2.25)* 43.78–1.65 (1.69–1.65)* 34.94–2.53 (2.60–2.53)*
Unique reflexions 16 629 (1186)* 105 524(7381)* 29 335(2139)*
Completeness for range (%) 100 (99.9)* 98.7 (98.5)* 99.9 (99.9)*
Multiplicity 6.5 (6.5)* 4.1 (4.1)* 13.1 (13.6)*
Rmerge 0.220 (0.920)* 0.068 (0.608)* 0.061 (0.629)*
I/σ(I) 6.3 (2.1)* 11.0 (2.2)* 23.4 (1.1)*
Wavelength (Å) 0.9686 0.9763 0.97949
Phasing MR MR MR
Rwork, Rfree (%) 24.2, 29.8 15.7, 18.1 22.6, 28.4
Number of atoms
protein, other, solvent 2133, 31, 44 4647, 164, 582 3367, 31, 0
B-factors (Å2)
protein, other, solvent 29.4, 28.6, 20.2 30.8, 21.6, 40.7 94.9, 135.7,—
rmsd bond (Å) 0.015 0.016 0.015
rmsd angle (°) 1.749 1.557 1.846
Ramachandran statistics
favoured, outliers (%) 96.30, 0.37 97.03, 0.17 90.20, 1.78
*Values in parentheses correspond to the highest resolution shell.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 3201
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the anchor helix resulting in the CFL1 phosphoacceptor poking in and out towards the ATP γ phosphate to
establish a constructive orientation for phosphoryl transfer (Figure 2B,D). This rock-and-poke mechanism is
different from the conventional catalytic mechanism of kinases. Usually, the phosphoacceptor residue is embed-
ded into an unstructured linear motif or a ﬂexible loop that transiently forms β-sheet-like hydrogen bonding to
the kinase activation loop for phosphoryl transfer [33]. In this regard, LIMK1 is unusual in that it catalyses tip
phosphorylation, rather than the common loop phosphorylation.
LIMK1 is a dual-speciﬁcity kinase
Conventionally, the depth of the phosphoacceptor residue pocket determines if a protein kinase is a Ser/Thr or
Tyr-speciﬁc enzyme [33]. The rock-and-poke mechanism would allow for variable phosphoacceptor positions
potentially explaining previous reports that LIMK1 exhibited dual substrate speciﬁcity [34]. To investigate this
possibility, we produced CFL1 substrate variants containing either a S3T or S3Y substitution in addition to the
wild-type protein. LIMK1, ATP and respective CFL1 variants were then incubated to allow for phosphorylation
(Figure 3A), and the mixtures analysed by mass spectrometry (Figure 3B). Under the chosen reaction condi-
tions, 80% of wild-type CFL1 (Ser3) and 50% of the CFL1 S3Y mutant were phosphorylated conﬁrming
LIMK1 as a dual-speciﬁcity kinase. Surprisingly, no phosphorylation was detected on the CFL1 S3T mutant
(Figure 3C). Large scale kinase studies have indicated that large hydrophobic residues (Leu, Phe, or Met) at the
activation loop DFG + 1 position confer kinases with selectivity for Ser over Thr residues [35]. Leu481 occupies
this position in LIMK1 and presumably creates steric hindrance for the binding of the branched Thr residue.
In this respect, the rock-and-poke mechanism conforms to the precedents of the more conventional loop
phosphorylation.
Figure 2. The rock-and-poke mechanism of catalysis.
(A) LIMK1 is composed of two N-terminal LIM domains, the PDZ domain and the kinase domain. The expression construct
LIMK1KD comprised the C-terminus only. (B) LIMK1KD (blue) in complex with ATPγS, bound to its physiological substrate CFL1
(green). In CFL1, the serine residue subjected to phosphorylation was mutated to cysteine, in order to trap the enzyme-substrate
complex (PDB ID 5L6W). A previously published LIMK1-CFL1 structure (PDB ID 5HVK) showed the complex after the reaction
(ADP and Phospho-CFL1 in white, LIMK1 omitted because its conformation was identical with the one shown in blue). The CFL1
binding angles differed by 12°. This rotation resulted in the CFL1 N-terminus poking into the LIMK1 active site (rock-and-poke
mechanism). (C) The CFL1 anchor helix was ﬁrmly attached to the LIMK1 docking interface. The CFL1 residue K112 was
co-ordinated by three LIMK1 residues. (D) LIMK1 bound its substrate ATPγS in the way typical for kinases. There were two hinge
hydrogen bonds to hold the adenine in position. K368 and N465 were adjusting the triphosphate. The CFL1 C3 side chain was
oriented for catalysis. For comparison, the enzyme-product complex with ADP and Phospho-CFL1 is again shown in white.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).3202
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LIMK1 is targeted by clinically tested kinase inhibitors
The conservation of the kinase domain ATP-binding pocket presents challenges for the design of selective inhi-
bitors, but also provides opportunities for drug repurposing. Indeed, the vast majority of clinically tested com-
pounds are multi-targeted kinase inhibitors. We utilised differential scanning ﬂuorimetry (DSF) [28] as an
initial screen to test LIMK1 for binding to a collection of these clinical molecules available commercially
through the Selleckchem L1200 compound library. Hits in this assay stabilise the protein’s melting temperature
(TM) proportionally to the negative log of the IC50 value (pIC50). In the presence of buffer alone LIMK1KD dis-
played a TM value of 49°C. A number of the tested compounds stabilised LIMK1KD substantially, with
PF-477736 (11 K) and dabrafenib (10 K) inducing the highest TM shifts (Figure 4A). For comparison, the
library was similarly screened for its potential to stabilise LIMK2KD. As expected, the best LIMK1KD binding
compounds also stabilised LIMK2KD (Figure 4C). However, several inhibitors displayed interesting isoform spe-
ciﬁcity, namely AZ 960 (LIMK1KD 6.0 K, LIMK2KD 0.1 K) and gandotinib (5.4 K, −0.5 K). These compounds
provide proof of principle that LIMK1 can be targeted selectively over LIMK2 as well as potential chemical
starting points for the development of LIMK1-speciﬁc inhibitors. All TM shift values are listed in
Supplementary Table S1.
A RapidFire mass spectrometry assay for IC50 determination
The DSF assay offers a robust format for screening with a high dynamic range, but conﬁrmation in an orthog-
onal in vitro kinase assay is desirable for hit validation as well as to compare results across different kinases. To
establish suitable assay conditions, we initially tested a set of 20 commercial peptides that are known to be
phosphorylated by a wide range of kinases as potential substrates for LIMK1 (Supplementary Table S2). No
activity towards these peptides was observed consistent with the divergent substrate-binding pocket of LIMK1
and its unusual rock-and-poke mechanism. We, therefore, switched to recombinant CFL1 as a known substrate
and employed a mass spectrometry assay to monitor LIMK1KD-dependent phosphorylation of CFL1 Ser3. An
ATP concentration of 800 mM was adopted for IC50 measurements corresponding to the kinase’s apparent KM
value for ATP. Analysis of the reaction mixtures by mass spectrometry revealed baseline-separated peaks for
the non-phosphorylated and phosphorylated (+80 Da) CFL1 proteins that enabled clear quantiﬁcation of the
Figure 3. LIMK1 is a dual-speciﬁcity kinase.
(A) CFL1 variants were tested as LIMK1KD substrates. AXG is the amino acid sequence of the CFL1 N-terminus. The X stands for S
(CFL1 wt), T and Y, respectively. Please note M1 was cleaved during expression in bacteria. (B) Deconvoluted mass spectra of the
reaction mixtures containing either CFL1 wt, S3T or S3Y. Phosphorylation induced an 80 Da shift to the CFL1 mass as indicated by
the red arrows. (C) Comparison of the CFL1 phosphorylation grades. Both CFL1 wt and S3Y were good LIMK1 substrates, which
makes LIMK1 a dual-speciﬁcity kinase. CFL1 S3T was not phosphorylated by LIMK1. The experiment was performed in triplicate.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 3203
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reaction product. Phosphomapping of the reaction product conﬁrmed that LIMK1KD phosphorylated CFL1 at
Ser3 only. To proﬁle the top hits from the DSF screening, we took advantage of a mass spectrometer equipped
with a RapidFire sample robot allowing for small reaction volumes (50 ml per reaction) and high performance
(90 min per 384 samples) as well as Agilent software for automated peak integration. Example inhibition
curves are shown in Figure 4B and reveal IC50 values for LIMK1 inhibition ranging from 4.4 nM (PF-477736)
to 430 nM (staurosporine). Overall, all the identiﬁed hits were conﬁrmed as LIMK1 inhibitors with excellent
agreement between the ranking of compounds by the DSF and RapidFire assays (Figure 4C).
Exploring the conformational space for inhibitor interaction with LIMK1KD
While several LIMK1 inhibitors are described in the literature [17,20], the absence of structural models for their
interaction limits the prospects of rationally optimising their binding potency and selectivity. To address this need
we performed further co-crystallisation trials with our recombinant LIMK1KD protein and solved the structures
of LIMK1 in complexes with the top screening hit PF-477736 (PDB ID 5NXC) as well as staurosporine (PDB ID
3S95) (Figure 5A). PF-477736 was developed as a checkpoint kinase-1 (Chk1) inhibitor and induces a ‘synthetic
lethal’ effect in DNA-damaged cancer cells by disrupting the S-G2 checkpoint [36]. The co-structure with LIMK1
showed an ATP-competitive binding mode with two hydrogen bonds between the diazapenyl moiety nitrogens
and the kinase hinge region, as well as a further bifurcated hydrogen bond between the carbonyl substituent and
the side chains of the gatekeeper residue Thr413 and catalytic lysine (Lys368, Figure 5B). Two additional hydro-
gen bonds were formed between the amide and primary amines of PF-477736 with the DFG motif Asp478 and
P-loop Lys347, respectively (Figure 5B). The natural product staurosporine is a widely studied promiscuous
kinase inhibitor [37]. Its binding mode exhibited similarly extended hydrophobic contact, but fewer electrostatic
interactions, perhaps reﬂecting its lower afﬁnity for LIMK1 (Figure 5A). As typically observed for this compound,
staurosporine formed two hydrogen bonds with the kinase hinge as well as an interaction with the backbone
carbonyl of the catalytic loop residue His464 (Figure 5C).
Comparison of the two inhibitor-bound structures revealed a signiﬁcant 10 Å shift in the position of the αC
helix as well as an 8 Å shift in the P-loop (Figure 5D). The LIMK1 complex with the type I inhibitor stauros-
porine showed a DFG-in αC-in conformation with an intact catalytic salt bridge between the β3 lysine and the
αC glutamate that is characteristic for an active kinase. Both the C-spine and the R-spine of the kinase were
intact, further conﬁrming the active conformation of the catalytic domain. No crystal structures were previously
solved using PF-477736 despite this compound entering clinical trials. However, PF-477736 was formerly
Figure 4. Identiﬁcation and conﬁrmation of LIMK1 inhibitors.
(A) The effect of 407 conventional kinase inhibitors on the LIMK1 thermal stability was determined in DSF assay. PF-477736
induced the highest shift with 11 K, staurosporine stabilised LIMK1 by 5.1 K. (B) The inhibitory potential of the best DSF hits
was probed in the RapidFire kinase activity assay. The dose-response curves for PF-477736 and staurosporine are plotted in
blue and red, respectively. (C) The results obtained from DSF and RapidFire assays were in excellent agreement. Several
inhibitors stabilised LIMK1, but not LIMK2. These inhibitors were isoform-speciﬁc (see also Supplementary Table S1).
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modelled into the CHK1 kinase structure as a classical type I inhibitor binding to an active αC-in conformation
(template PDB ID 4FT5, [38]). Our structure revealed a distinct ﬂipped conformation of PF-477736 that
switched the hydrogen bond interaction of the diazapenyl moiety carbonyl from the hinge +3 position (Chk1
model, [38]) to the gatekeeper and catalytic lysine (LIMK1, PDB ID 5NXC). Consequently, the catalytic salt
bridge was broken in the LIMK1 co-structure and a DFG-in αC-out conformation was observed (Figure 5D).
Interestingly, the LIMK1 R-spine was broken due to the outward shift of the αC. The Met388 site chain was
removed from the R-spine and the resulting space ﬁlled with the Phe399 side chain. These major rearrange-
ments were accompanied by a closed conformation of the P-loop which packed closely with the phenyl ring of
PF-477736 (Figure 5B). The weaker interaction of staurosporine was associated with a more open conformation
of the P-loop resulting in less packing interactions and higher B factors.
Strategies to enhance LIMK1 kinase activity for enzymology studies
LIMK1 can be phosphorylated under physiological conditions by the kinase PAK1 (Figure 1A) [39].
Recombinant LIMK1KD puriﬁed from insect cells was not phosphorylated as determined by mass spectrometry
(Figure 6A). We incubated this protein with different constructs of PAK1 in vitro to assess their impact on
LIMK1 phosphorylation state and catalytic activity. All phosphorylation experiments were performed as three
independent repeats. The isolated PAK1 kinase domain demonstrated robust phosphorylation of LIMK1KD,
Figure 5. Examples of inhibitors bound to LIMK1.
(A) Binding properties and chemical structures of PF-477736 (blue) and staurosporine (red). (B) The LIMK1-PF-477736 complex
(PDB ID 5NXC). Beside the hinge interactions including the gatekeeper residue T413, the inhibitor bridged the DFG motif, the
β3 sheet and the P loop. Parts of the model were removed for clarity. (C) The LIMK1-staurosporine complex (PDB ID 3S95). In
addition to the two salt bridges to the LIMK1 hinge, there is only the interaction to H464 prior to the β7 sheet. This explains the
low afﬁnity of the compound. (D) Overlay of the PF-477736 (blue) and staurosporine (red) structures, as seen from the active
site in the direction of the N-lobe. Staurosporine bound LIMK1 in an active-like conformation with intact K-E salt bridge, while
PF-477736 binding induced an inactive conformation, characterised by a 9.6 Å outwards shift of αC helix, with no K-E salt
bridge formed. The dark cloud represents the inhibitor binding site.
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 3205














 user on 14 February 2020
whereas no signiﬁcant phosphorylation of LIMK1KD was observed using the kinase-dead variant PAK1KD
D389N or using full-length PAK1 containing its autoinhibitory domain (Figure 6A). Phosphomapping con-
ﬁrmed that the single phosphorylation occurred at LIMK1 Thr508 located within the kinase domain activation
loop (data not shown). Of note, LIMK1KD alone also showed a low level of autophosphorylation when mixed
with ATP and MgCl2 (Figure 6A), although the physiological relevance of this result remains unclear.
Importantly, phosphorylation at Thr508 increased the LIMK1KD activity towards its substrate CFL1 by more
than 10-fold (Figure 6B), providing an option to improve the sensitivity of the RapidFire activity assay. Thr508
was situated in the LIMK1 activation segment. Upon phosphorylation, it interacted with Arg483 [24], likely sta-
bilising the interface recognised by the CFL1 anchor helix.
We also explored whether mutations in the CFL1 anchor helix could lead to enhancements in the LIMK1KD
activity. The mutant CFL1 A118W was engineered to increase the potential size of the protein–protein inter-
action surface. Most interestingly, this CFL1 variant proved to be a more favourable substrate for LIMK1KD
than the wild-type protein (Figure 6C). This potentially reﬂects π stacking interactions of the tryptophan with
the loop C-terminal to the LIMK1 APE motif. Perhaps surprisingly, this CFL1 position appeared rather tolerant
to substitution. The introduction of a proline in the mutant CFL1 A118P would be expected to break the
anchor helix. However, this mutation did not alter the CFL1 substrate properties (Figure 6C). This result sug-
gested that the key CFL1 residues for LIMK1 interaction occur at the N-terminal end of the anchor helix.
Figure 6. Modulating the LIMK1 enzyme and the CFL1 substrate properties.
(A) Recombinant PAK1KD phosphorylated recombinant LIMK1KD, while PAK1FL and PAK1KD D389N were not active. Please
note the basal LIMK1 autophosphorylation. (B) Phosphorylation increased LIMK1 kinase activity by more than factor 10.
PAK1KD did not phosphorylate CFL1 at all. (C) Binding of the CFL1 anchor helix to the LIMK1 docking interface. Residues
important for binding and residues subjected to mutagenesis are highlighted. (D) Impact of amino acid exchanges in the CFL1
anchor helix on the CFL1 substrate properties. CFL1 K112 was indispensable for substrate recognition. The introduction of
tryptophan in position 118 made CFL1 an even better LIMK1 substrate. Breaking the anchor helix in position 118 did not
signiﬁcantly alter substrate recognition. All experiments were performed in triplicate.
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Finally, as a negative control we introduced the mutation CFL1 K112A which breaks ion pair interactions with
LIMK1 Asp549 and Asp551. As anticipated from the structural model, CFL1 K112A was only poorly phos-
phorylated by LIMK1 (Figure 6C), highlighting the critical role of this residue in binding.
Discussion
When analysing the co-ordinates of our LIMK1–ATPγS–CFL1 complex (PDB ID 5L6W), the distribution of B
factors was remarkable. While the B factors of residues in the LIMK1 kinase core were relatively low, the B
factors in the entire CFL1 molecule were high. This indicated a lack of CFL1 rigidity due to the transient,
dynamic nature of the enzyme-substrate interaction. We then compared our structure model to the recently
published LIMK1–ADP–Phospho-CFL1 model (PDB ID 5HVK) [24]. The difference in the CFL1 binding
angle was intriguing, further supporting the idea of a loosely bound CFL1 subunit. The structural models
resulted from different crystal forms where crystal packing differences have the potential to inﬂuence the CFL1
binding angle. However, we regard the two structural models as two snapshots of how the enzyme-substrate
complex might look in solution at a certain point in the catalytic process. From these two snapshots, the
rock-and-poke mechanism suggested herein was deduced. It may be interesting in future work to explore this
mechanism by molecular dynamics simulation.
Our LIMK1–ATPγS–CFL1 crystals were characterized by an unusually high water content of ∼70%. CFL1, in
particular, was not stabilised by many crystal contacts and in the crystal lattice rather formed a bridge between
two LIMK1 molecules. Therefore, the CFL1 loop regions retained some ﬂexibility in the crystal. Several residues
in the CFL1 loops were Ramachandran outliers despite extensive model building. However, the unusual confor-
mations of CFL1 Lys44, Ile131 and Ala157 fall at positions far from the binding interface and are therefore
technical rather than key structural features.
In the eukaryotic cell, CFL1 is found either in its free form or in its actin ﬁlament-bound form. Importantly,
actin binding is mediated by the CFL1 anchor helix — the same helix that is indispensable for LIMK1 substrate rec-
ognition. Consequently, LIMK1 can only phosphorylate CFL1 in its free form. The assays and the structure models
presented herein will hopefully facilitate the development of potent and speciﬁc chemical probes for LIMK1 func-
tional studies. For example, would LIMK1 inhibition alone be sufﬁcient to reduce the phosphorylation state of the
CFL1 pool, or would this still differ according to cell type and developmental stage due to the occurrence of LIMK2,
TESK1/2 and the phosphatase slingshot? It also remains unclear whether LIMK1 can phosphorylate other substrate
proteins in addition to ADFs. A greater understanding of these questions would help to inform on the safety and
efﬁcacy of potential LIMK1-speciﬁc therapeutics as a future treatment for diseases such as FXS and ALS.
Conclusions
The physiological role of LIMK1 is to phosphorylate the very N-terminus (Ser3) of its substrate proteins.
Therefore, LIMK1 substrate recognition and catalytic mechanism differ from what is common in conventional
kinases. Substrates such as CFL1 bind speciﬁcally to the LIMK1 docking interface via their anchor helices that
are <100 residues distant from the phosphoacceptor residue. All LIMK inhibitors published to date target the
ATP-binding site. Small molecules mimicking the CFL1 anchor helix might represent a worthwhile alternative
approach to inhibit LIMK1 kinase activity. The requirement to phosphorylate the tip of a polypeptide chain is
met by the rock-and-poke mechanism of catalysis. As a consequence, LIMK1 is a dual-speciﬁcity kinase that
phosphorylates both Ser and Tyr residues. However, phosphorylation of the branched Thr residue was not
observed. The lessons from enzymology helped to design and to improve a RapidFire mass spectrometry-based
activity assay that combined the use of the physiological substrate CFL1 with keeping the throughput at least
medium (∼250 data points per hour). With our limited inhibitor screen a set of LIMK1 inhibitors was identi-
ﬁed, some of which notably were isoform speciﬁc (no binding to LIMK2). The ﬁrst crystal structures of LIMK1
in complex with inhibitors revealed the plasticity of the kinase domain. Depending on the bound inhibitor, the
P loop and the αC helix shifted substantially. This deepened understanding of LIMK1 enzymology and struc-
ture will hopefully facilitate future inhibitor screening and medicinal chemistry efforts.
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